Disc Medicine, Inc.
IRONNasdaqHealthcare · Pharmaceutical Preparations · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Operating income | −$236.0M | −$129.7M | −$91.1M | −$47.5M | −$30.9M | −$817,028 |
| Net income | −$212.2M | −$109.4M | −$76.4M | −$46.8M | −$36.0M | −$812,495 |
| Total assets | $806.9M | $496.8M | $368.0M | $200.2M | $92.4M | $122.1M |
| Total liabilities | $67.1M | $53.2M | $22.9M | $23.6M | $14.8M | $4.8M |
| Equity | $739.8M | $443.6M | $345.1M | $176.6M | −$64.2M | $5.0M |
| EPS (diluted) | $-6.01 | $-3.96 | $-3.42 | $-45.05 | $-40.95 | — |
| Shares out. | 34.6M | 24.7M | 19.0M | 43.2M | 43.0M | 15.6M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −28.7%
- Return on assets
- −26.3%
- Return on capital (ROCE)
- −30.6%
- Liabilities / assets
- 8.3%
- Debt / equity
- 0.09×
- Book value / share
- $21.40
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 13.80safe
- Accruals / assets
- −3.9%clean
- Piotroski F-Score
- 3/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 warning● 3 good- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1/2Recruitingreadout ~2026-09Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
- Phase 3Active Not Recruitingreadout ~2026-09Study of Bitopertin in Participants With EPP or XLP (APOLLO)
- Phase 2Recruitingreadout ~2026-10Study of DISC-0974-201 in Participants With IBD and Anemia
- Phase 2Recruitingreadout ~2027-02A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)
- Phase 1Recruitingreadout ~2027-06A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)
- Phase 2/3Enrolling By Invitationreadout ~2028-06HELIOS: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP or XLP
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Ra Capital Management, L.P.Passive (13G)Jan 7, 2026
- Atlas Venture Fund X, L.P.Activist (13D)Dec 17, 2025
- Fmr LlcPassive (13G)Nov 5, 2025
- Ai Dmi LlcActivist (13D)Oct 22, 2025
- Frazier Life Sciences Public Fund, L.P.Passive (13G)Aug 14, 2025
- Wellington Management Group LlpPassive (13G)Aug 12, 2025
- Paradigm Biocapital Advisors LpPassive (13G)May 15, 2025
- Orbimed Advisors LlcActivist (13D)Mar 12, 2025
- Bain Capital Life Sciences Opportunities Iii, LpPassive (13G)Feb 14, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Savage William JacobOfficer — Chief Medical Officer | Apr 13, 2026 | Sell | 3,531 | $66.12 |
| Franchi Jean M.Officer — Chief Financial Officer | Apr 13, 2026 | Sell | 400 | $69.00 |
| Savage William JacobOfficer — Chief Medical Officer | Mar 2, 2026 | Sell | 4,392 | $65.52 |
| Franchi Jean M.Officer — Chief Financial Officer | Feb 25, 2026 | Sell | 353 | $69.06 |
| Franchi Jean M.Officer — Chief Financial Officer | Feb 17, 2026 | Sell | 4,075 | $62.86 |
| Khara RahulOfficer — Chief Legal Officer | Feb 17, 2026 | Sell | 2,853 | $62.86 |
| Stephenson PamelaOfficer — Chief Commercial Officer | Feb 17, 2026 | Sell | 5,531 | $62.86 |
| Savage William JacobOfficer — Chief Medical Officer | Feb 17, 2026 | Sell | 3,256 | $62.86 |
| Yu Jonathan Yen-WenOfficer — Chief Operating Officer | Feb 17, 2026 | Sell | 3,231 | $62.86 |
| Quisel John DOfficer — Chief Executive Officer | Feb 17, 2026 | Sell | 13,264 | $62.86 |
| Khara RahulOfficer — Chief Legal Officer | Feb 10, 2026 | Grant | 17,000 | $0.00 |
| Stephenson PamelaOfficer — Chief Commercial Officer | Feb 10, 2026 | Grant | 17,000 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 5.7M | 10.6 | +2.3% |
| Apr 30, 2026 | 5.5M | 15.6 | +5.7% |
| Apr 15, 2026 | 5.2M | 12.4 | -4.0% |
| Mar 31, 2026 | 5.5M | 9.5 | +21.4% |
| Mar 13, 2026 | 4.5M | 7.7 | +5.3% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 5, 2026
- Costs from exit or disposalFeb 27, 2026
- Results of operationsFeb 26, 2026
- Regulation FD disclosureFeb 17, 2026
- Regulation FD disclosure · Other material eventFeb 13, 2026
- Results of operations · Regulation FD disclosureJan 12, 2026
- Other material eventDec 8, 2025
- Results of operationsNov 6, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.